Company intelligence / Profile preview

SCRH

Ownership: Private
Employees: ~1000
Development stage: Commercial

Overview

Sarah Cannon Research Institute is one of the world’s leading organizations conducting community-based oncology clinical trials. It has contributed to pivotal research that led to the majority of new cancer therapies approved by the FDA over the past decade. The institute operates more than 1,000 active clinical trials at any time and has conducted over 850 first-in-human studies since inception.

Therapeutic areas: OncologyHematology
Modalities: Small moleculeMonoclonal antibodyAntibody-drug conjugateCell therapy
Industry: Contract Research Organization

Partnerships

IQVIA – strategic collaboration on global oncology trial accelerationMultiple partnerships with pharmaceutical and biotech companies globally for trial execution.

Beyond the preview

Go deeper on SCRH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCRH.

Explore the full profile